Calusterone (NSC-88536): a poor substitute for fluoxy-mesterone (NSC-12165) in the treatment of advanced breast cancer.
D000728:Androgens / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004487:Edema / Q000139:chemically induced; D005260:Female; D005474:Fluoxymesterone / Q000627:therapeutic use*; D006261:Headache / Q000139:chemically induced; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D006934:Hypercalcemia / Q000139:chemically induced; D008111:Liver Function Tests; D008777:Methyltestosterone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009325:Nausea / Q000139:chemically induced; D009362:Neoplasm Metastasis; D014770:Virilism / Q000139:chemically induced
D000728:Androgens; D000970:Antineoplastic Agents; D003520:Cyclophosphamide; D005474:Fluoxymesterone; D008777:Methyltestosterone